EdgarLookup

Verrica Pharmaceuticals Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Verrica Pharmaceuticals Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $14.34M Nov 14, 2025
Q3 2025 Sep 30, 2024 ($1.78M) Nov 14, 2025

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q2 2025 Jun 30, 2025 $12.70M Aug 12, 2025
Q1 2025 Mar 31, 2025 $3.44M May 13, 2025
Q3 2024 Sep 30, 2024 ($1.78M) Nov 5, 2024
Q2 2025 Jun 30, 2024 $5.18M Aug 12, 2025
Q1 2025 Mar 31, 2024 $3.83M May 13, 2025
Q3 2024 Sep 30, 2023 $2.92M Nov 5, 2024
Q2 2024 Jun 30, 2023 $182.0K Aug 14, 2024
Q1 2024 Mar 31, 2023 $37.0K May 13, 2024
Q3 2023 Sep 30, 2022 $8.32M Nov 9, 2023
Q2 2023 Jun 30, 2022 $214.0K Aug 8, 2023
Q1 2023 Mar 31, 2022 $431.0K May 9, 2023
Q3 2022 Sep 30, 2021 $0 Nov 7, 2022
Q2 2022 Jun 30, 2021 $0 Aug 11, 2022
Q1 2022 Mar 31, 2021 $12.00M May 9, 2022

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($274.0K) Nov 14, 2025
Q3 2025 Jun 30, 2025 $204.0K Nov 14, 2025
Q2 2025 Jun 30, 2025 $204.0K Aug 12, 2025
Q2 2025 Mar 31, 2025 ($9.74M) Aug 12, 2025
Q1 2025 Mar 31, 2025 ($9.74M) May 13, 2025
Q3 2025 Mar 31, 2025 ($9.74M) Nov 14, 2025
Q3 2025 Sep 30, 2024 ($22.86M) Nov 14, 2025
Q3 2025 Jun 30, 2024 ($17.19M) Nov 14, 2025
Q2 2025 Jun 30, 2024 ($17.19M) Aug 12, 2025
Q1 2025 Mar 31, 2024 ($20.33M) May 13, 2025
Q2 2025 Mar 31, 2024 ($20.33M) Aug 12, 2025
Q3 2025 Mar 31, 2024 ($20.33M) Nov 14, 2025
Q3 2024 Sep 30, 2023 ($24.80M) Nov 5, 2024
Q2 2024 Jun 30, 2023 ($10.99M) Aug 14, 2024
Q3 2024 Jun 30, 2023 ($10.99M) Nov 5, 2024
Q1 2024 Mar 31, 2023 ($6.59M) May 13, 2024
Q2 2024 Mar 31, 2023 ($6.59M) Aug 14, 2024
Q3 2024 Mar 31, 2023 ($6.59M) Nov 5, 2024
Q3 2023 Sep 30, 2022 $83.0K Nov 9, 2023
Q2 2023 Jun 30, 2022 ($10.17M) Aug 8, 2023

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $1.63M Nov 14, 2025
Q2 2025 Jun 30, 2025 $1.51M Aug 12, 2025
Q1 2025 Mar 31, 2025 ($8.13M) May 13, 2025
Q3 2025 Sep 30, 2024 ($20.70M) Nov 14, 2025
Q2 2025 Jun 30, 2024 ($15.21M) Aug 12, 2025
Q1 2025 Mar 31, 2024 ($18.60M) May 13, 2025
Q3 2024 Sep 30, 2023 ($23.92M) Nov 5, 2024
Q2 2024 Jun 30, 2023 ($11.62M) Aug 14, 2024
Q1 2024 Mar 31, 2023 ($7.09M) May 13, 2024
Q3 2023 Sep 30, 2022 $1.45M Nov 9, 2023
Q2 2023 Jun 30, 2022 ($9.12M) Aug 8, 2023
Q1 2023 Mar 31, 2022 ($7.41M) May 9, 2023
Q3 2022 Sep 30, 2021 ($11.77M) Nov 7, 2022
Q2 2022 Jun 30, 2021 ($10.73M) Aug 11, 2022
Q1 2022 Mar 31, 2021 $60.0K May 9, 2022
Q3 2021 Sep 30, 2020 ($9.64M) Nov 12, 2021
Q2 2021 Jun 30, 2020 ($8.63M) Aug 10, 2021
Q1 2021 Mar 31, 2020 ($9.88M) May 7, 2021
Q3 2020 Sep 30, 2019 ($6.54M) Nov 9, 2020
Q2 2020 Jun 30, 2019 ($7.52M) Aug 5, 2020